Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
Beatriz GrosNikolas PlevrisNathan Constantine-CookeMathew LyonsClaire O'HareColin NobleIan D ArnottGareth-Rhys JonesCharlie W LeesLauranne A A P DerikxPublished in: United European gastroenterology journal (2023)
Multiple successive switches from IFX originator to biosimilars are effective and safe in patients with IBD, irrespective of the number of IFX switches.
Keyphrases